Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

Inclusion Criteria : * Infertility and desire to conceive, justifying ART treatment * Age between 18 and 36 years, inclusive, at time of informed consent * Body mass index (BMI) 18 to 30 kilogram per square meter (kg/m\^2), inclusive * Regular spontaneous menstrual cycles of 21 to 35 days * Presence of both ovaries * Transvaginal ultrasound within 6 weeks and hysterosalpingogram, hysterosonogram or hysteroscopy within 2 years prior to beginning OCP treatment, showing no clinically significant uterine abnormality, which, in the Investigator's opinion, could impair embryo implantation or pregnancy continuation * Normal early follicular phase (Day 2-4) serum FSH level, according to the local laboratory * Normal serum thyroid stimulating hormone (TSH) level, according to the local laboratory * Papanicolaou (PAP) smear test without clinically significant abnormalities within the last 6 months prior to beginning oral contraceptive therapy, * Negative pregnancy test prior to beginning GnRH-agonist therapy * Male partner with semen analysis which is at least adequate for ICSI within last 6 months prior to beginning GnRH agonist therapy, according to local laboratory * Willing and able to comply with the protocol * Voluntary provision of written informed consent, prior to any study-related procedure that was not part of normal medical care, with the understanding that the subject could withdraw consent at any time without prejudice to her future medical care, and * Willingness to provide follow-up information on babies born as part of this study * For subjects recruited at PK sub-study centers, voluntary provision of written informed consent to participate in the PK sub-study Exclusion Criteria: * Subject who require a starting dose of FSH greater than (\>) 150 international unit per day (IU/day), in the opinion of the Investigator * Screening ultrasound demonstrating more than 12 follicles less than (\<) 11 mm mean diameter in either ovary * Two or more previous ART cycles (consecutive or not) with poor response to gonadotrophin, defined as less than or equal to (=\<)3 oocytes retrieved * Three or more previous consecutive ART cycles without a biochemical or clinical pregnancy * Previous failure of fertilization with ICSI * A previous ART attempt in which there were no adequate or motile sperm before or after the processing of ejaculated sperm * Previous severe OHSS * History or presence of tumors of the hypothalamus or pituitary gland * History or presence of ovarian, uterine or mammary cancer * History or presence of ovarian enlargement or cyst of unknown etiology, or presence of ovarian cyst \>25 mm on the day of randomization * Presence of endometriosis Grade III - IV * Presence of uni- or bilateral hydrosalpinx * Abnormal gynecological bleeding of undetermined origin * Contraindication to being pregnant and/or carrying a pregnancy to term * History of \>= 3 clinical or preclinical (absence of gestational sac) miscarriages due to any cause * Extra-uterine pregnancy within the 3 months prior to randomization * Clinically significant concurrent disease that would have compromised subject safety or interfered with the study assessments * Known infection with human immunodeficiency virus (HIV), hepatitis B or C virus in the female or male partner * Known allergy or hypersensitivity to human gonadotrophin preparations or to compounds that are structurally similar to any of the other medications administered during the study * Any medical condition, which in the judgment of the Investigator may have interfere with the absorption, distribution, metabolism or excretion of r-hFSH * Any active substance abuse or history of drug, medication or alcohol abuse within 5 years before screening * ART cycle and/or ovarian stimulation within 30 days prior to informed consent * Entered previously into this study or simultaneous participation in another clinical trial * Subject is a smoker consuming more than 5 cigarettes per day * In the opinion of the Investigator, either assisted hatching or pre-implantation genetic diagnosis is indicated for the subject * Planning to undergo experimental procedures such as blastomere biopsy, or * Any known autoimmune disease